<< Back to News

System Formulary Update
Skyrizi (risankizumab-rzaa)

Situation

Skyrizi (risankizumab-rzaa) 600 mg/10 mL intravenous solution was approved for addition to the health system formulary at the August 2022 System Pharmacy and Therapeutics Committee meeting.

Background

The following medication was reviewed: Skyrizi (risankizumab-rzaa) 600 mg/10 mL intravenous solution

Assessment/Recommendations

System P&T voted to include the following products on the UNC Health Medication Formulary with restriction to outpatient/clinic use only (ie, no inpatient use):

• Skyrizi (risankizumab-rzaa) 600 mg/10 mL intravenous solution

Note: Stock of this formulary product may vary at individual entities

Formulary/Epic changes will Go-Live on Tuesday, October 4, 2022.